Brown Advisory’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q1
Sell
-6,650
Closed -$241K 1079
2019
Q4
$241K Buy
+6,650
New +$204K ﹤0.01% 935
2019
Q2
Sell
-39,512
Closed -$1.04M 1346
2019
Q1
$1.04M Buy
39,512
+290
+0.7% +$6.87K ﹤0.01% 797
2018
Q4
$766K Buy
39,222
+314
+0.8% +$6.16K ﹤0.01% 814
2018
Q3
$762K Sell
38,908
-2
-0% -$38 ﹤0.01% 875
2018
Q2
$644K Buy
38,910
+4,767
+14% +$72.7K ﹤0.01% 910
2018
Q1
$485K Buy
34,143
+5,842
+21% +$86.3K ﹤0.01% 845
2017
Q4
$413K Buy
28,301
+16,817
+146% +$236K ﹤0.01% 942
2017
Q3
$145K Buy
+11,484
New +$146K ﹤0.01% 1141
2017
Q2
Sell
-18,856
Closed -$279K 1257
2017
Q1
$279K Buy
+18,856
New +$305K ﹤0.01% 1006
2016
Q4
Sell
-10,841
Closed -$196K 1172
2016
Q3
$196K Buy
+10,841
New +$212K ﹤0.01% 1016

Other funds holding HZNP

Brown Advisory's HZNP Position: Q1 2020 in Review

Brown Advisory sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q1 2020, closing a stake of 6,650 shares — an estimated $241K sold.

Brown Advisory first reported a position in HZNP in Q3 2016 and held it in 10 quarters. The position peaked at $1.04M in Q1 2019. 295 funds tracked by Wall St. Rank hold HZNP as of Q1 2020.

  • Brown Advisory reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q1 2020 after selling out during the quarter.
  • Brown Advisory sold 6,650 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q1 2020, an estimated $241K.
  • Brown Advisory first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2016 and held it in 10 quarters.
  • Brown Advisory's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $1.04M in Q1 2019.
  • 295 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q1 2020.

Based on Brown Advisory's 13F filing for Q1 2020, filed 15 May 2020.